Artiva Biotherapeutics (NASDAQ:ARTV – Get Free Report) and Imunon (NASDAQ:IMNN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends and earnings.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Artiva Biotherapeutics and Imunon, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Artiva Biotherapeutics | 1 | 0 | 4 | 1 | 2.83 |
| Imunon | 1 | 0 | 1 | 0 | 2.00 |
Artiva Biotherapeutics presently has a consensus price target of $39.00, indicating a potential upside of 297.15%. Imunon has a consensus price target of $10.00, indicating a potential upside of 449.45%. Given Imunon’s higher possible upside, analysts clearly believe Imunon is more favorable than Artiva Biotherapeutics.
Risk & Volatility
Profitability
This table compares Artiva Biotherapeutics and Imunon’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Artiva Biotherapeutics | N/A | -73.15% | -62.74% |
| Imunon | N/A | -341.23% | -153.79% |
Earnings and Valuation
This table compares Artiva Biotherapeutics and Imunon”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Artiva Biotherapeutics | $250,000.00 | 971.00 | -$83.86 million | ($3.54) | -2.77 |
| Imunon | N/A | N/A | -$14.49 million | ($5.16) | -0.35 |
Imunon has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Imunon, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
4.5% of Imunon shares are owned by institutional investors. 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 2.8% of Imunon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Artiva Biotherapeutics beats Imunon on 9 of the 13 factors compared between the two stocks.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
About Imunon
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon’s DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
